134 related articles for article (PubMed ID: 31347926)
41. Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Ishihara H; Yamaguchi S; Sugitani T; Kosakai Y
Clin Drug Investig; 2019 Dec; 39(12):1213-1221. PubMed ID: 31552641
[TBL] [Abstract][Full Text] [Related]
42. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).
Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Fujii S; Kakiuchi S; Fujiwara H; Kameda H; Tamura M; Kaku K
J Diabetes Investig; 2017 Nov; 8(6):766-775. PubMed ID: 28107773
[TBL] [Abstract][Full Text] [Related]
43. Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.
Okada K; Kotani K; Ebihara K; Yamazaki H; Ishibashi S
Int J Clin Pharmacol Ther; 2016 Dec; 54(12):1004-1008. PubMed ID: 27615008
[TBL] [Abstract][Full Text] [Related]
44. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
[TBL] [Abstract][Full Text] [Related]
45. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Schwartz SL; Akinlade B; Klasen S; Kowalski D; Zhang W; Wilpshaar W
Diabetes Technol Ther; 2011 Dec; 13(12):1219-27. PubMed ID: 21854192
[TBL] [Abstract][Full Text] [Related]
46. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Tobe K; Maegawa H; Nakamura I; Uno S
Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).
Odawara M; Matsuhisa M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
Expert Opin Pharmacother; 2020 Oct; 21(14):1771-1780. PubMed ID: 32693663
[TBL] [Abstract][Full Text] [Related]
48. Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Wang H; Yao G; Chen X; Ouyang J; Yang J
Diabetes Res Clin Pract; 2019 Nov; 157():107867. PubMed ID: 31568801
[TBL] [Abstract][Full Text] [Related]
49. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Hwang YC; Kim JH; Lee BW; Lee WJ
Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
[TBL] [Abstract][Full Text] [Related]
50. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
51. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Takase T; Nakamura A; Miyoshi H; Yamamoto C; Atsumi T
Endocr J; 2017 Mar; 64(3):363-367. PubMed ID: 27980239
[TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Wilding JP; Ferrannini E; Fonseca VA; Wilpshaar W; Dhanjal P; Houzer A
Diabetes Obes Metab; 2013 May; 15(5):403-9. PubMed ID: 23163880
[TBL] [Abstract][Full Text] [Related]
53. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A
Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
[TBL] [Abstract][Full Text] [Related]
54. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study.
Kaku K; Chin R; Naito Y; Iliev H; Ikeda R; Ochiai K; Yasui A
Expert Opin Drug Saf; 2020 Feb; 19(2):211-221. PubMed ID: 31769309
[No Abstract] [Full Text] [Related]
55. Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Alkabbani W; Gamble JM
Drug Des Devel Ther; 2021; 15():3057-3069. PubMed ID: 34285473
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan.
Ishida Y; Murayama H; Shinfuku Y; Taniguchi T; Sasajima T; Oyama N
Expert Opin Drug Saf; 2020 May; 19(5):625-631. PubMed ID: 32228183
[No Abstract] [Full Text] [Related]
57. Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):613-23. PubMed ID: 25643044
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Kaku K; Kadowaki T; Seino Y; Okamoto T; Shirakawa M; Sato A; O'Neill EA; Engel SS; Kaufman KD
Diabetes Obes Metab; 2021 Sep; 23(9):2099-2108. PubMed ID: 34033212
[TBL] [Abstract][Full Text] [Related]
59. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Takahashi K; Cho KY; Nakamura A; Miya A; Miyoshi A; Yamamoto C; Nomoto H; Niwa H; Takahashi K; Manda N; Kurihara Y; Aoki S; Ito YM; Atsumi T; Miyoshi H
J Diabetes Investig; 2019 Mar; 10(2):429-438. PubMed ID: 30136403
[TBL] [Abstract][Full Text] [Related]
60. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
